Urological Disorders Therapeutics to 2017 - Large Number of Licensing Deals for Approved Products Reflects a Pessimistic R&D Future
In 2010, the global urological disorders market was estimated to be worth $8.1 billion, representing a Compound Annual Growth Rate (CAGR) of 7.9% between 2002 and 2010. In the same year, Urinary Incontinence (UI) and Benign Prostatic Hyperplasia (BPH) combined accounted for 79% of the total urological disorders market with revenue of $6.5 billion. Solifenacin and tolterodine for UI and dutasteride and tamsulosin for BPH dominated the market in 2010 and generated $2 billion and $1.8 billion respectively.
View full press release